Maze Therapeutics' Chief Medical Officer Sold 100% of His Direct Holdings. Here's What This Means for Investors.
The Big Market Report Take
This clinical-stage biotech focused on precision medicines for kidney and metabolic diseases just reported a notable insider sale.
Not financial advice. The Big Market Report aggregates news for informational purposes only. Nothing on this site constitutes investment advice. Equities and other securities are subject to market risk. Always do your own research and consult a qualified financial advisor before making any investment decisions. Full disclaimer →
Never miss a story
More from this section
- 2 Durable Income BDCs That Can Go On OffenseSeeking Alpha40m ago
- Applied Optoelectronics: Momentum Is Real, And Estimates Still Look Too LowSeeking Alpha45m ago
When Should You Claim Social Security if You Don't Actually Need the Money?The Motley Fool47m ago- The Potential Economic Impact of Ending Birthright CitizenshipBloomberg Markets54m ago